A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects.


Journal

Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 29 03 2018
revised: 13 12 2018
accepted: 03 01 2019
pubmed: 12 3 2019
medline: 31 3 2020
entrez: 12 3 2019
Statut: ppublish

Résumé

Deep brain stimulation (DBS) is an emerging treatment for severe obsessive-compulsive disorder (OCD). We compared the efficacy of ventral capsule/ventral striatal (VC/VS) and anteromedial subthalamic nucleus (amSTN) DBS in the same patients and tested for mechanistic differences on mood and cognitive flexibility and associated neural circuitry. The possible synergistic benefit of DBS at both sites and cognitive behavioral therapy was explored. Six patients with treatment-refractory OCD (5 men; Yale-Brown Obsessive Compulsive Scale score >32) entered double-blind counterbalanced phases of 12-week amSTN or VC/VS DBS, followed by 12-week open phases when amSTN and VC/VS were stimulated together, in which optimal stimulation parameters were achieved and adjunctive inpatient cognitive behavioral therapy was delivered. OCD and mood were assessed with standardized scales and cognitive flexibility with the Cambridge Neuropsychological Test Automated Battery Intra-Extra Dimensional Set-Shift task. Diffusion-weighted and intraoperative magnetic resonance imaging scans were performed for tractography from optimally activated electrode contacts. DBS at each site significantly and equivalently reduced OCD symptoms with little additional gain following combined stimulation. amSTN but not VC/VS DBS significantly improved cognitive flexibility, whereas VC/VS DBS had a greater effect on mood. The VC/VS effective site was within the VC. VC DBS connected primarily to the medial orbitofrontal cortex, and amSTN DBS to the lateral orbitofrontal cortex, dorsal anterior cingulate cortex, and dorsolateral prefrontal cortex. No further improvement followed cognitive behavioral therapy, reflecting a floor effect of DBS on OCD. Both the VC/VS and amSTN are effective targets for severe treatment-refractory OCD. Differential improvements in mood and cognitive flexibility and their associated connectivity suggest that DBS at these sites modulates distinct brain networks.

Sections du résumé

BACKGROUND
Deep brain stimulation (DBS) is an emerging treatment for severe obsessive-compulsive disorder (OCD). We compared the efficacy of ventral capsule/ventral striatal (VC/VS) and anteromedial subthalamic nucleus (amSTN) DBS in the same patients and tested for mechanistic differences on mood and cognitive flexibility and associated neural circuitry. The possible synergistic benefit of DBS at both sites and cognitive behavioral therapy was explored.
METHODS
Six patients with treatment-refractory OCD (5 men; Yale-Brown Obsessive Compulsive Scale score >32) entered double-blind counterbalanced phases of 12-week amSTN or VC/VS DBS, followed by 12-week open phases when amSTN and VC/VS were stimulated together, in which optimal stimulation parameters were achieved and adjunctive inpatient cognitive behavioral therapy was delivered. OCD and mood were assessed with standardized scales and cognitive flexibility with the Cambridge Neuropsychological Test Automated Battery Intra-Extra Dimensional Set-Shift task. Diffusion-weighted and intraoperative magnetic resonance imaging scans were performed for tractography from optimally activated electrode contacts.
RESULTS
DBS at each site significantly and equivalently reduced OCD symptoms with little additional gain following combined stimulation. amSTN but not VC/VS DBS significantly improved cognitive flexibility, whereas VC/VS DBS had a greater effect on mood. The VC/VS effective site was within the VC. VC DBS connected primarily to the medial orbitofrontal cortex, and amSTN DBS to the lateral orbitofrontal cortex, dorsal anterior cingulate cortex, and dorsolateral prefrontal cortex. No further improvement followed cognitive behavioral therapy, reflecting a floor effect of DBS on OCD.
CONCLUSIONS
Both the VC/VS and amSTN are effective targets for severe treatment-refractory OCD. Differential improvements in mood and cognitive flexibility and their associated connectivity suggest that DBS at these sites modulates distinct brain networks.

Identifiants

pubmed: 30853111
pii: S0006-3223(19)30063-0
doi: 10.1016/j.biopsych.2019.01.017
pmc: PMC6467837
pii:
doi:

Banques de données

ISRCTN
['ISRCTN18430630']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

726-734

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J012009/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 104631/Z/14/Z
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Références

Psychol Med. 2014 Dec;44(16):3515-22
pubmed: 25065708
Mol Psychiatry. 2016 Sep;21(9):1272-80
pubmed: 26303665
Behav Res Ther. 2012 Mar;50(3):203-9
pubmed: 22325808
J Neurosci. 2016 Nov 9;36(45):11489-11495
pubmed: 27911752
Neurosurgery. 2010 Sep;67(3 Suppl Operative):ons213-21; discussion ons221
pubmed: 20679927
Psychiatry Res. 2015 May 30;227(1):114-25
pubmed: 25681005
Am J Psychiatry. 2007 Feb;164(2):335-8
pubmed: 17267798
Biol Psychiatry. 2005 Mar 1;57(5):510-6
pubmed: 15737666
Acta Neurochir Suppl. 2013;117:53-9
pubmed: 23652657
Am J Psychiatry. 2002 Feb;159(2):269-75
pubmed: 11823270
PLoS One. 2013 Apr 29;8(4):e61892
pubmed: 23658616
Neuropsychopharmacology. 2010 Jan;35(1):4-26
pubmed: 19812543
Lancet Psychiatry. 2016 Aug;3(8):730-739
pubmed: 27318812
J Neurosci. 2018 Feb 21;38(8):2106-2117
pubmed: 29358360
Biol Psychiatry. 2010 Dec 1;68(11):1016-22
pubmed: 20951978
Mol Psychiatry. 2010 Jan;15(1):64-79
pubmed: 18490925
Lancet. 1999 Oct 30;354(9189):1526
pubmed: 10551504
Nat Rev Neurosci. 2010 Jul;11(7):503-13
pubmed: 20559337
Biol Psychiatry. 2017 Apr 15;81(8):708-717
pubmed: 27769568
World Neurosurg. 2011 Jul-Aug;76(1-2):164-72; discussion 69-73
pubmed: 21839969
Front Syst Neurosci. 2017 Apr 27;11:25
pubmed: 28496402
Magn Reson Med. 2012 Dec;68(6):1846-55
pubmed: 22334356
Biol Psychiatry. 2010 Mar 15;67(6):535-42
pubmed: 20116047
Arch Gen Psychiatry. 2010 Oct;67(10):1061-8
pubmed: 20921122
J R Soc Med. 1992 Jul;85(7):399-402
pubmed: 1629849
Neuroimage. 2007 Jan 1;34(1):144-55
pubmed: 17070705
Brain Connect. 2011;1(3):169-83
pubmed: 22433046
Med Biol Eng Comput. 2009 Jan;47(1):21-8
pubmed: 18936999
Br J Psychiatry. 2003 May;182:404-11
pubmed: 12724243
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3216-3221
pubmed: 28265059
J Neurosci. 2011 Jul 13;31(28):10392-402
pubmed: 21753016
J Psychiatry Neurosci. 2017 Nov;42(6):378-385
pubmed: 28632120
Neurosurgery. 2010 Dec;67(2 Suppl Operative):437-47
pubmed: 21099570
J Neurosci. 2013 Mar 13;33(11):4804-14
pubmed: 23486951
N Engl J Med. 2008 Nov 13;359(20):2121-34
pubmed: 19005196

Auteurs

Himanshu Tyagi (H)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom; The National Hospital for Neurology and Neurosurgery, London, United Kingdom.

Annemieke M Apergis-Schoute (AM)

Department of Psychology, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, United Kingdom.

Harith Akram (H)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom; The National Hospital for Neurology and Neurosurgery, London, United Kingdom.

Tom Foltynie (T)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom; The National Hospital for Neurology and Neurosurgery, London, United Kingdom.

Patricia Limousin (P)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom; The National Hospital for Neurology and Neurosurgery, London, United Kingdom.

Lynne M Drummond (LM)

Highly Specialised Service for OCD and BDD (England), SW London and St George's NHS Trust, London, United Kingdom.

Naomi A Fineberg (NA)

Highly Specialised Service for OCD and BDD (England), Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, United Kingdom; Centre for Clinical & Health Research Services, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.

Keith Matthews (K)

Division of Neuroscience, School of Medicine, University of Dundee, Dundee, United Kingdom; Advanced Interventions Service, NHS Tayside, Ninewells Hospital and Medical School, Dundee, United Kingdom.

Marjan Jahanshahi (M)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom.

Trevor W Robbins (TW)

Department of Psychology, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, United Kingdom.

Barbara J Sahakian (BJ)

Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, United Kingdom.

Ludvic Zrinzo (L)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom; The National Hospital for Neurology and Neurosurgery, London, United Kingdom.

Marwan Hariz (M)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom; The National Hospital for Neurology and Neurosurgery, London, United Kingdom.

Eileen M Joyce (EM)

Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, United Kingdom; The National Hospital for Neurology and Neurosurgery, London, United Kingdom. Electronic address: e.joyce@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH